Method for O-acylating 7-acylamino-cephalosporadesic acids

ABSTRACT

A method for O-acylating the 3-hydroxymethyl group of 7acylaminocephalosporadesic acids by reaction with an azolide and new O-acyl-7-acylaminocephalosporadesic acids in which the O-acyl group is derived from an alkoxyalkanoic acid or an amino acid.

United States Patent Berges Sept. 16, 1975 METHOD FOR'O ACYLATING [56] References Cited 7-ACYLAMINO-CEPHALOSPORADESIC UNITED STATES PATENTS ACIDS 3,634,417 1/1972 Attenburrow et al 260/243 c [75] Inventor; David A, Barges, Audubgn Pa. 3,706,746 12/1972 Bosshardt 260/243 C [73] Assignee: SmithKline Corporation, OTHER PUBLICATIONS Philadelphia, Staab, Angew. Chem. Inter. 1211., 1; 351-356 (1962). [22] Filed: May 22,1972

Primary Examiner-Nich0las S. Rizzo [21] Appl' 255632 Attorney, Agent, or Firm-Joan S. Keps; Richard D.

Related U.S. Application Data gg William g r n [63] Continuation-impart of Ser. No. 141,380, May 7,

1971, abandoned. [57] ABSTRACT A method for O-acylating the 3-hydroxymethyl group [30] Fore'gn Apphcatmn Pnonty Data of 7-acylaminoccphalosporadesic acids by reaction Apr. 10, United Kingdom an azolide and new O acy]-7 acylaminocephalosporadesic acids in which the Oacyl [52] U.S. Cl. 260/243 C; 424/246 group is derived f an alkoxyalkanoic acid or an [51] Int. Cl. C07D 501/02 amino acid [58] Field of Search 260/243 C 6 Claims, No Drawings METHOD FOR O-ACYLATING 7-ACYLAMINO-CEPHALOSPORADESIC ACIDS This application is a continuation-inpart of Sen- No. 141,380, filed May 7, l97l, now abandoned.

except that any hydroxy, amino or carboxy groups have protecting groups; i

This invention relates to a method for the prepara- 5 tion of O-acyl-7-acylaminocephalosporadesic acids, in r particular to the step in that method which comprises o-acylaftmg the 3 h'ydr(.)xym,ethyl 99 is an acyl group for antibacterial cephalosporins, exacylaminocephalosporadesic acids. In addition, this incept that an easily eliminated B-substttuent is not vention relates to new O-acyl-7 10 present, acylaminocephalosporadesic acids; in particularto compounds in which the O-acylgroup is derived from 0 an alkoxyalkanoic acid'or an amino acid. H

The 3-hydroxymethyl grup of cephalosporadesic C acids isknown to be difficult to acylate. Lactone formation or isomerization to the A -isomers is reported to is the same as occur during attempted O-acylations; E. vVan Heyningen, Advances in Drug Research, Volume 4, pages 0 28-29 (1967). This invention provides'a method of li preparing a wide variety. of O-acyl-7- acylaminocephalosporadesic acids in good yield.

O-Acyl-7-acylaminocephalosporadesic acids having except that any hydroxy, amino and thiol groups antibacterial activity are prepared by the method of have protecting groups; this invention. According to the method of thisinvention, the 3- hydroxymethyl group of 7- acylaminocephalosporadesic acids'is'O-acylated by reaction with an azolide at about 0 to 50C. The term azolide denotes an N'acyl heterocycle the 'hetemcy' is a quasi-aromatic five-membered ring containing at cle beinga quasi-aromaticfive=membered ring containleast two nitrogen atoms; and ing at least two nitrogen atoms. Staab, Angew, Chem. M is hydrogen an alkali metal Cation or a quaternary Internal. Edit 1:351 1962). Preferably, the azolide is ammonium Cation an N-acylimidazole, l acyl-l,2,4,triazole or l-acyl lnformula m abbve, l,2,3 -triazole. Advantageously, the amide is an N- acylimidazole. i i

The method according to this invention is repre sented as follows: 1 R.C

o R,'-( i-HN R,--C-HN S .N CH2OCR2 COOM III

in which: represents any of the variety of acyl groups which may is an acyl group for antibacterial cephalospor'ins;

u 'R,-c r

is the same as 0 ll R,C-

R is benzyl a-hydroxybenzyl a-aminobenzyl a-aminocyclohexadienylmethyl thienylmethyl a-hydroxythienylmethyl 'a-aminothienylmethyl tetrazolylmethyl pyridylthiomethyl phenoxymethyl phenylthiomethyl benzofurylmethyl isothiazolylmethyl oz-met hoxy-I: ,4-dichlorobenzyl cyanomethyl sydnonemethyl In Formula III above,

represents any acyl group which may be present as an O-substituent on the 3-hydroxymethyl group of antibacterial cephalosporins and which is derived from a carboxylic acid of the formula which is capable of forming an azolide of the formula R therefore, cannot contain an easily eliminated B-substituent such as halo. Exemplary of groups represented by R are lower alkyl, aryl, aralkyl, heteroaryl and heteroaralkyl. These groups may have substituents and functional groups (other than easily eliminated B-substituents) such as amino, mercapto, alkylmercapto, hydroxy, alkoxy and carboxy. Examples of R groups, all of which may be substituted as outlined above, are the following:

lower alkyl having l6 carbon atoms, straight chain or branched phenyl naphthyl benzyl thienyl furyl The process of this invention is preferably carried out at neutral to mildly basic pH in an inert solvent, such as tetrahydrofuran, benzene, chloroform or preferably, dimethylformamide'. The reaction is carried out at about 0 to 50C., preferably at room temperature. Conveniently, the progress of the reaction is monitored and its completion is determined by thin-layer chromatography.

The 7-acylaminocephalosporadesic acid is preferably used in the process of this invention in the form of an alkali metal salt.

The azolide is prepared by reacting a carboxylic acid with a diazolide of carbonic acid. This process is represented as follows:

in which R is as defined above.

' This reaction is preferably carried out in an inert solvent such as tetrahydrofuran, benzene, chloroform or preferably, dimcthylformamide, at about room temperature. Conveniently, the resulting azolide is not isolated but is used in the resulting solution in the O-acylation process. Advantageously, 7- acylaminocephalosporadesic acid, preferably as an alkali metal salt, is added directly to the solution containing the azolide.

Any amino, hydroxy, thiol or carboxy groups in the 7-acylaminocephalosporadesic acid or azolide reactants of the method of this invention are protected during the reaction by standard protecting groups. For example, t-butoxycarbonyl may be used to protect amino groups or trichloroethoxycarbonyl to protect amino, hydroxy and thiol groups. Carboxy groups may be protected by converting to the t-butyl ester. The protecting groups are removed after the O-acylation by standard procedures. For example, a t-butoxycarbonyl group on an amino group may be removed by treating with an acid such as trifluoroacetic acid and neutralizing the resulting salt, the trichloroethoxycarbonyl group may be removed by treating with zinc and acetic acid and the t-butyl ester may be hydrolyzed by treating with trifluoroacetic acid.

Other protecting groups may be used such as trityl to protect amino groups; the trityl group may be removed by treating with acid. Trimethylsilyl may be used to protect hydroxy or thiol groups in R Also, hydroxy groups may be protected by tetrahydropyranyl groups and thiol groups may be protected with pmethoxybenzyl. The trimethylsilyl and tetrahydropyranyl protecting groups may be removed by treating with aqueous acid. p-Methoxybenzyl groups may be removed using trifluoroacetic acid.

The 7-acylaminocephalosporadesic acids of Formula I are prepared by methods known to the art, for example, by enzymatic hydrolysis of 7-acylaminocephalosporanic acids or by N-acylation of 7- aminocephalosporadesic acid.

The O-acyl-7-acylaminocephalosporadesic compounds of this invention are represented by Formula III above in which:

R, is Z-thienylmethyl, 4-pyridylthiomethyl, cyanomethyl, tetrazolylmethyl, sydnone-3-methyl, whydroxybenzyl, a-hydroxy-Z-thienylmethyl, a-aminobenzyl, a-aminocyclohexa-l,4-dienylmethyl or a-amino-Z-thienylmethyl;

is an acyl group derived from an alkoxyalkanoic acid such as methoxyacetic, B-methoxypropionic, y-methoxybutyric, or S-methoxyvaleric acid or an amino acid such as glycine,'pheriylglycine, alanine, phenylalanine, methionine, cysteine,lysine, serine, aspartic acid, B-alanine, 'y-aminobutyric acid or S-aminovaleric acid. Advantageous compounds of Formula 111 are, for ex-. ample, the following:

O-methoxyacetyl-7-(2-thienylacetamido)cephalosporadesic acid O-y-methoxybutyryl-7-( aaminophenylacetamido cephalosporadesic acid I O.glycy1-7( 2-thienylacetamido )cepha1osporadesic I acid O -cysteinyl-7-(2-thienylacetarnido)cephalos-.

' poradesic acid 4 O-B-alany1-7-(oz-aminophenylacetamido)cephalosporadesic acid. Ccphalosporins having antibacterial activity are prepared by the process of this invention. The compounds, including the compounds of this invention, have activity against Gram-positive and Gram-negatve bacteria. Exemplary of the microorganisms against which they are effective are Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Streptococcus pyogenes and S1reptococcusfaecalis. These cephalosporins are formulated for use and used to treat and prevent bacteria] infections by standard procedures.

, The followingexamples are not limiting but are illustrative of the method of this invention.

EXAMPLE 1 General Procedure To 0.012 mole of a carboxylic acid in about 20 ml. of dry N,N-dimethylformamide is added 0.012 mole of a diazolide of carbonic acid. After stirring for from 0.5 to 1.5 hours, 0.010 mole of the appropriate 7- acylaminocephalosporadesic acid, preferably in the form of an alkali metal salt, is added either as a solid or in N,N-dimethylformamide solution. The progress of the reaction is monitored by thin-layer chromatography. When the reaction has reached completion, the mixture is poured into from 0.5 to 2.0 l. of ether, and the insoluble alkali metal salt of the O-acyl 7- acylaminocephalosporadesic acid is filtered off. The product is decolorized with charcoal and recrystallized. The product is separated from any unreacted 7- acylaminocephalosporadesic acid salt by converting the latter to Y the corresponding 7- acylaminocephalosporanolactone by mild acid treatment of the mixture (elg. stirring a methanol solution with an acidic ion-exchange resin such as Amberlite IR- 120H), then converting the product back into the alkali metal salt form whichis se'parated from the lactone by recrystallization.

The alkali metal salt is converted to the O-acy1-7 -v acylaminocephalosporadesic acid'by mild acid treatment. For example, an acidic ion-exchange resin may be used. I. i I

EXAMPLE) By the procedure of Example 1, using the following carboxylic acids: I

acetic acid J propionic acid butyric acid 6 N,N-carbonyldiimidazole and 7-( 2thienylacetamido)- cephalosporadesic acid, the following products are ob tained, respectively:

7-(2-thieny1acetamido)cephalosporanic acid O-propionyl-7-(2-thieny1acetamido)cephalosporadesic acid O-butyry1-7-( Z-thienylacetamido)cephalosporadesic acid.

EXAMPLE 3 To 1.09 g. of methoxyacetic acid in ml. of dry N,N-dimethylforrnamide' is added 1.96 g. of N,N- carbonyldiimidazole in one portion as a.solid. After stirring for minutes, 3.76 g. of sodium 7-(2- thienylacetamidoacephalosporadesate is added as a solid. The progress of the reaction is monitored by thin layer chromatography using fluorescent silica gel plates and an 80:20:3 chloroformmethanol-formic acid solventsystem. The reaction mixture is stirred for 26 20 hours, thenp'oured into 1 liter ofether and filtered. The solid obtained is dissolved in wet methanol, charcoal is added and the mixture is stirred for about 30 minutes, then filtered The resulting solution is concentrated and acetone is slowly added. After refrigerating for 3 days and theri filtering, sodium O-methoxyacetyl-7-(2- thienylacetamido)cephalosporadesate hemihydrate is obtained.

Theory Found C 44.63 44.55 H 3.96 4.05 N 6. 12 6.05

This product has antibacterial activity, in particular against Escherichia coli.

Dissolving sodium O-methoxyacety1-7-( 2 thienylacetamido)cephalosporadesate hemihydrate in methanol, then stirring the solution with an excess of an acidic ion-exchange resin, filtering and removing the solvent in vacuo gives O-methoxyacetyl-7-(2- thienylacetamido)cephalosporadesic acid.

EXAMPLE 4 To 1.84 g. of N-t-butoxycarbonylglycine in 10 ml. of dry N,N-dimethylforrnariiide is added 1.70 g. of N,N 5O carbonyldiimidazole ,in one portion as a solid. After stirring for 30 minutes, 3.28 g. of sodium 7-(2- thienylacetamido)cephalosporadesate is added as a solid. The progress of theireaction is monitored by thinlayer chromatography using fluorescent silica gel plates and-an 8:2:1;chloroformisopropanol-formic acid solventsystem. The reaction mixture is stirred for 45 hours, then poured into 1 liter of ether and filtered. The solid obtained is dissolved in methanol and decolorized with charcoal. The solution is concentrated to about 75 m1..and diluted with225 ml. of ether. The resulting gel is filteredoff, then dissolved in methanol and stirred withan excess of an acidic ion-exchange resin. After filtering off the resin, the solvent is removed in vacuo to give O-(N-t-butoxycarbonylglycyl)-7-(2- thienylacetamido)cephalosporadesic acid.

Treating anether-acetone: solution of O-(Ntbutoxycarbonylglycyl )-7-( Z-thienylacetamido )cephalosporadesic acid with 30% sodium 2-ethylhexanoate in isopropanol gives the sodium salt hemihydrate.

This product has antibacterial activity against Grampositive and Gram-negative bacteria, in particular against Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Streptococcus pyogenes and Strepto coccus faecalis.

To an ice-cooled flask equipped with a calcium sulfate drying tube and magnetic stirring and containing 20 ml. of trifluoroacetic acid is added 1.71 g. of O-( N-tbutoxycarbonylglycyl )-7-( 2-thienylacetamido )cephalosporadesic acid. The reaction mixture is stirred in the ice bath for l hour and then allowed to warm to room temperature over 30 minutes. The mixture is then poured slowly into 250 ml. of rapidly stirred ether. The resulting solid is filtered off and dissolved in water containing 21 minimum amount of acetone. To the solution is added 5% aqueous sodium bicarbonate solution to raise the pH to 3.0. The resulting gel is filtered off, washed with water and then acetone and dried to give O-glycyl-7-(2-thienylacetamido)cephalosporadesic acid hydrate.

c l-l N O s H O (429.484)

Theory Found C 44.75 44.85 H 4.46 4.37 N 9.74 9.2l

EXAMPLE 5 To 0.612 g. of pivalic acid in ml. of dry N,N-dimethylformamide is added 0.972 g. of N,N- carbonyldiimidazole. The mixture is stirred for 35 minutes, then 1.88 g. of sodium 7-(2-thienylacetamido)- cephalosporadesate is added. The progress of the reaction is monitored by thin-layer chromatography using fluorescent silica gel plates and an 8:2:1 chloroformisopropanol-formic acid solvent system. After 45 hours, the reaction mixture is poured into 700 ml. of ether. The resulting solid is filtered off and dissolved in methanol and decolorized with charcoal. The methanol is removed in vacuo, and wet acetone is added to the residue. The insoluble material is filtered off. The filtrate is evaporated to dryness in vacuo, and the residue is taken up in wet methanol. The solution is treated with acidic ion-exchange resin, filtered and stripped to dryness in vacuo. Ethyl acetate is added to the residue. The resulting solution is allowed to stand overnight. Ether is added to the solution, and the insoluble material is filtered off. The filtrate is treated with a 30% solution of sodium 2-ethylhexanoate in isopropanol. The precipitate is filtered off and dissolved in wet acetone.

The solution is evaporated to dryness in vacuo to give sodium O-pivaloyl-7-( 2-thienylacetamido )cephalosporadesate hydrate.

Theory Found This product has antibacterial activity, for example against Staphylococcus aureus, Streptococcus pyogenes and Diplococcus pneumoniae.

The above prepared sodium salt is dissolved in methanol and treated with acidic ion-exchange resin to give, after filtering and removing the solvent in vacuo, O- pivaloyl-7-(2-thienylacetamido)cephalosporadesic acid hydrate.

EXAMPLE 6 Using benzoic acid, N,N-carbonyldi-( l,2,4-triazole) and potassium 7-(Z-thienylacetamido)cephalosporadesate in the procedure of Example I, the product is O- benzoyl-7-(2-thienylacetamido )cephalosporadesic acid.

EXAMPLE 7 Using benzoic acid, N,N-carbonyldiimidazole and benzyltrimethylammonium 7-(2- benzofurylacetamido)cephalosporadesate [prepared by treating potassium 7-(Z-benzofurylacetamido)cephalosporadesate with an acidic ion-exchange resin and treating the resulting 7-(Z-benzofurylacetamido)cephalosporadesic acid with benzyltrimethylammonium hydroxide] in the procedure of Example 1, the product is O-benzoyl-7-( Z-benzofurylacetamido )cephalosporadesic acid.

Similarly, using benzyltrimethylammonium 7- phenylthioacetamidocephalosporadesate (prepared by treating potassium 7-phenylthioacetamidocephalosporadesate with an acidic ion-exchange resin and treating the resulting 7-phenylthioacetamidocephalosporadesic acid with benzyltrimethylammonium hydroxide), the product is O-benzoyl-7-phenylthioacetamidocephalosporadesic acid.

EXAMPLE 8 Using 2-thiophenecarboxylic acid, N,N'- carbonyldiimidazole and potassium 7-( 2- thienylacetamido)cephalosporadesate in the procedure of Example 1, the product is O-(2-thenoyl)-7-(2- thienylacetamido)cephalosporadesic acid.

Similarly, using 2-furoic acid, N,N'- carbonyldiimidazole and potassium 7-phenylthioacetamidocephalosporadesate, the product is O-(2- furoyl)-7-phenylthioacetamidocephalosporadesic acid.

By the same procedure, using Z-naphthoic acid, N,N-carbonyldiimidazole and potassium 7-phenylthioacetamidocephalosporadesate, the product is O-(2- naphthoyl)-7-phenylthioacetamidocephalosporadesic acid.

EXAMPLE 9 By the procedure of Example 1, the reaction of propionic acid, N,N-carbonyldiimidazole and 7- phenylacetamidocephalosporadesic acid gives 7- phenylacetamido-O-propionylcephalosporadesic acid.

Similarly, using in place of propionic acid, the following:

hexanoic acid phe'nylacetic acid the products are,"respcctively:

O-he xanoyl-7-phenylacetamidocephalosporadesic acid 7rphenylacetamido-O-phenylacetylcephalos-' poradesic acid. l v V EXAMPLE 10 By the procedure of Example 1, the" reaction'of benzoic acid, N,N-carbonyldiimidazo'le and 7-(5- isothiazolylacetamido )cephalosporade sic acid gives 0- benzoyl-7-( S-isothiazolylacetamido )cephalosporades ic acid.

EXAMPLE 1 1 According to the procedure of Example l propionic acid in N,N-dimethylformamide is allowed to react with N,N'-carbonyldiimida'zole, then '7-(0z-rne'thoxy- 3,4-dichlorophenylacetamido)cephalo'sporadesic acid,

. as the sodium salt, is added and the reaction mixture is stirred until thin-layer chromatography shows the reactionis complete. The reaction mixture is then poured into ether and filtered to give, after working up by the procedure of Example 1 7- (oz-methoxy -3,4- dichlorophenylacetarnidoj o-propionylcephalosporades'icacid.

EXAMPLE 12 trichloroethoxycarbony]) D-mandelie acid, m'.p. 157-15s c. V j,

A suspension of 4.26 "g. of O'-(2,2,2-

trichloroethoxycarbonyl)-D-mandelic acid iri 47 g. of thionyl chloride is heated at reflux for 4 hours. The excess thionyl chloride is removed in vacuo to leave solid O-2,2,2-trichloroethoxycarboriylj-D inandeloyl chloide-mp- 7- A solution of,7-aminocephalosporanic acidina mixture of acetone, andnac ueouslsodium bicarbonate is treated with O-(2,2,2-trichloroethoxycarbonyl)-D- mandeloyl ehloride to give 7-[O (2,2,2- trichloroethox ycarbonyl )-D-rnandelamido cephalosporanic acid. The sodium s'alt prepared .by treating with sodium 2-ethylhexanoate.

Sodium ,7[O 2,2,2-trichloroethoxycarbonyli D- mandelamidoJcephaIospQradesate (6.0 'g.), obtained by enzymatie deaeetylation of sodium 7 -[.O (2,2 ,2- trichloroethoxycarbonyl )D-mandelamidojcephalosporanate, is allowed to react with 1.5 g. of N- propionylimidazole in ml. of dry N,N-dimethylformamide, and the reaction mixture is worked up ac cording to the procedure of Example 1 to give O-propionyl- 10 7-[O-(2,2,2*trichloroethoxycarbonyl)-D mandelamidolcephalosporadesic acid.

'A suspension of 0.60 g. of activated-zinc dust in 6.0 ml. of 60% aqueous acetic acid is stirred for 15 minutes, and 0.60 g. of O-propionyl-7-[O-(2,2,2- trichloroethoxycarbonyl)D-mandelamidolcephalosporadesic acid is added. The reaction mixture is stirred for 3 hours, then diluted with 20 ml. of water and filtered. The solid is washed. with 50% aqueous acetic acid. The filtrate is acidified to pH 1.5 with 3N hydrochloric acid and extracted with ethyl acetate. The ethyl acetate extract is stripped to dryness in vacuo and the residue triturated withether to give O-propionyl-7-( D- mandelamido)cephalosporadesic acid.

Similarly, using N-benzoylimidazole in place-of N- propionylimidazole, the product is O-benzoyl-7-(O- mandelamido)cephalosporadesic acid.

EXAMPLE 13 By the procedure of Example 1, the reaction of a lower alkanoic acid, N,N-carbonyldiimidazole and sodium 7-[a-(t-butoxycarbonylamino)-1 ,4- cyclohexadienylacetamido]cephalosporadesate, ob-. tained by converting 7-[D-oz-(t-butoxycarbonylamino) l,4-cyclohexadienylacctamido]cephalosporanic acid to the sodium salt and subjecting the salt to enzymatic hydrolysis, gives 7-[D-a (t-butoxycarbonylamino)- l ,4- cyclohexadienylacetamido]-O-lower alkanoylcephalosporadesic acid. j Treating the product with trifluoroacetic acid by the procedure of Example 4 gives 7-(D-a-amino-l,4- cyclohexadienylacetamido )-O-lower alkanoylcephalosporadesic acid. I

EXAMPLE 14 ,By the procedure of Example 1, the reaction of propionic acid, N,N-carbonyldiimidazole and sodium 7- [D-oz-(t-butoxycarbonylarriinojphenylacetamido]cephalosporadesate, obtained by converting 7-[D-a -(tbutoxycarbonylamino )phenylace tarnido]cephalosporanic acid to the sodium salt and subjecting the salt to enzymatic hydrolysis, gives 7-[D-a-(tbutoxycarbonylamino )phenylacetamido -O-propionylcephalosporadesic acid. 7

A mixture 7 of 7-[D-a-(t- .butoxycarbonylamino)phenylacetarr ido] o-propionylcephalosporadesic acid and trifluoroacetic acid is stirred in an'ice bath for 1 hour, then is allowed to warm to room temperature over 30 minutes. The mixture is then poured slowly into ether with rapid stirring to give, after working up by the procedure of Example 4, 7-(D-a-aminophenylacetamido)-O-propionylcephalosporadesic acid.

EXAMPLE 15 Using 2-furoic acid, N,N'-carbonyldiimidazole and sodium 7-phenoxyacetamidocephalosporadesate in the procedure of Example 1, the productis O-(2-furoyl)-7- phenoxy acetamidocephalosporadesic acid.

EXAMPLE 1 6 Using, in the procedure of Example- 1, propionic acid, N,N"-carbonyldiimidazole and sodium 7-(1- tetrazolylacetamido)cephalosporadesate, prepared by converting 7-( l -tetrazolylacetamido )cephalosporanic acid to the sodium salt and then subjecting it to enzymatic hydrolysis, the product is O-propionyl-7-(ltetrazolylacetamido)cephalosporadesic acid;

' By the same uprocedure, using sodium 7-(4- pyridylthioacetamido)cephalosporadesate, prepared by enzymatic hydrolysis of sodium- 7-(4- pyridylthioacetamido)cephalosporanate, the productis O-propionyl-7-( 4-py'ridylthioacetamido )cephalosporadesic acid. 1

EXAMPLE l7 Using N-t-butoxycarbonylmethionine, N,N carbonyldiimidazole and sodium 7-( 2- thienylacetamido )cephalosporadesate in the procedure of Example 4, O-methionyl-7-(2-thienylacetamido)- ce phalosporadesic acid is obtained.

EXAMPLE I 8 Example 4 is followed using N-t-butoxycarbonyl-2,2- dimethylthiazolidine-4-carboxylic acid (R. B. Woodward et al., J. Am. Chem. Soc. 88:852, 1966), N,N- carbonyldiimidazole and sodium 7-(2- thienylacetamido)cephalosporadesate to give, after treatment with trifluoroacetic acid at room temperature, O-cysteinyl-7-(Z-thienylacetamido)cephalosporadesic acid.

EXAMPLE 19 By the procedure of Example 4, the reaction of N-t-butoxycarbonyl- O-( 2,2,2-trifluorol benzyloxycarbonylaminoethyl)-L-serine (F. Weygard et, al., Chem. Ber. 101:923, 1968), N,N- carbonyldiimidazole and sodium 7-(2- thienylacetamido)cephalosporadesate gives O-[N-tbutoxycarbonyl-O-( 2,2,2-trifluorol benzyloxycarbonylaminoethyl)-L-seryl]-7-(2- thienylacetamidocephalosporadesic acid. This product is treated with a mixture of trifluoroacetic acid and anisole containing one equivalent of HBr. The HBr salt is isolated and treated in aqueous solution with an anionexchange resin in methyl isobutyl ketone to give O-( L- seryl)-7-( 2-thienylacetamido)cephalosporadesic acid.

EXAMPLE 20 Using N-t-butoxycarbonylglycine, N,N- carbonyldiimidazole and the appropriate sodium cephalosporadesate (prepared by enzymatic hydrolysis of the corresponding cephalosporanic acid) in the procedure of Example 4, the following products are obtained:

O-glycyl-7-( 4-pyridylthioacetamido )cephalosporadesic acid O-glycyl-7-cyanoacetamidocephalosporadesic acid O-glycyl-7-( l-tetrazolylacetamido)cephalosporadesic acid O-glycyl-7( 3-sydnoneacetamido )cephalosporadesic acid O-glycyl-7-mandelamidocephalosporadesic acid O-glycyl-7-( a-hydroxythien-Z-ylacetamido )cephalosporadesic acid O-glycyl-7-( a-aminophenylacetamido )cephalosporadesic acid O-glycyl-7-( a-aminol ,4-cyclohexadienl ylacetamido)cephalosporadesic acid O-glycyl-7-,( a-aminothien-2-ylacetamido )cephalosporadesic acid.

EXAMPLE 2 l EXAMPLE 22 Using, in the procedure of Example 18, N-tbutoxycarbonyl-Z,2-dimethylthiazolidine-4-carboxylic acid, N,N'-carbonyldiimidazole and the appropriate sodium 7-acylcephalosporadesate, the following products are obtained:

O-cysteinyl-7-(4-pyridylthioacetamido)cephalosporadesic acid O-cysteinyl-7-cyanoacetamidocephalosporadesic acid O-cysteinyl-7-( l-tetrazolylacetamido )cephalosporadesic acid O-cysteinyl-7( 3-sydnoneacetamido)cephalosporadesic acid O-cysteinyl-7-mandelamidocephalosporadesic acid O-cysteinyl-7-(a-hydroxythien-Z-ylacetamido)cephalosporadesic acid O-cysteinyl-7-( oz-aminophenylacetamido )cephalosporadesic acid O-cysteinyl-7-( a-amino-l ,4-cyclohexadienlylacetamido)cephalosporadesic acid O-cysteinyl-7-( a-aminothien-Z-ylacetamido )cephalosporadesic acid.

EXAMPLE 23 Using N-t-butoxycarbonyl-O-(Z,2,2-trifluorol benzyloxy-carbonylaminoethyl )-L-serine, N,N carbonyldiimidazole and the appropriate sodium 7-acylcephalosporadesate in the procedure of Example 19, the following products are obtained:

O-seryl-7-(4-pyridylthioacetamido')cephalosporadesic acid O-seryl-7-cyanoacetamidocephalosporadesic acid O-seryl-7-( l -tetrazolylacetamido )cephalosporadesic acid O-seryl-7-( 3 -sydnoneacetamido )cephalosporadesic acid O-seryl-7-mandelamidocephalosporadesic acid O-seryl-7-(a-hydroxythien-2-ylacetamido)cephalosporadesic acid O-seryl-7-( a-aminophenylacetamido )cephalosporadesic acid O-seryl-7-( a-amino- 'l ,4-cyclohexadien- I ylacetamido)cephalosporadesic acid O-seryl-7-( a-aminothin-Z-ylacetamido )cephalos-" poradesic acid.

EXA LE 24 By the procedure of'Example 4, NJ-butoxycarbonylphenylglycine, N,N"-carbonyldiimidazole and the corresponding sodiurrr z7-ac'ylcephalosporadesate-are re acted to give the followingproductsz O-phenyl glycyl-7-( 4 pyridylthioacetamido )cephalosporadesic acid i O-phenylglycyl 7 cyanoacetamidocephalosporadesic O-phenylglycyl-7- ltetrazolylacetamido)cephalosporadesic acid poradesic acid J i O-phenylglycyl-7 mandelarn'idocephalosporadesic' 3 acid I i O-phenylg lycyl-7-(a-hydroxythien-2-ylacetamido) cephalosporadesicacid I i O-phenylglycyl-7-(a-aminophenylacetainido)cephalosporadesic acid i i ylacetamido)cephalosporadesic acid W Q O-phenylglycyl-7-( a-aminothien-Z-ylactamido} cephalosporadesic acid.

EXAMPLE 25 Using N-tbutoxycarbonylalanine, N,N-carbonyldiimidazole and the appropriate sodium 7r-acylcephalosporadesate according towt he procedure of Example 4, the following products are obtained:

O-alanyl-7-( 4-pyridyltio acetamido )cephalosporadesic acid v V O-alanyl-7-cyanoacetamidocep halosporadesic acid O'alanyl-7-( l-tetrazolylacetamido)cephalosporadesic acid O-alanyl-7-( 3-sydnoneacetamido)cephalosporadesic O-alanyl-7-mandelamidocephalosporadesic acid O-alanyl-7(a-hydroxythien-2-ylacetamido )cephalos poradesic acid v .1 r

O-alanyl-7-( a-aminophenylacetamido )cephalos poradesic acid O-alanyl-7-( oz-aminol ,4-cyclohexadien-l ylacetamido)cephalosporadesic acid O-alanyl-7-(a-aminothiemZ-ylacetamido)cephalosporadesic acid. r 2

' 7 EXAMPLE 26 I Using N-t-hutoxycarbonylp'henylalanine, N,N- carbonyldiimid azol e" and the appropriate sodium 7-acylcephalosporadesate according to the procedure of Example 4, the following products are obtained:

O-phenylalanyl-7-(4-pyridylthioacetamido)cephalosporadesic acid g v O-phenylalanyl-7-cyan0acetamidocephalosporadesic acid i O-phenylalanyl 7-'( 1-tetrazolylacetamido)cephalos- O-phenylalanyl 7-(3-sydnoneacetamido)cephalosporadesicacid l O-phenylalanyl 7-mandelamidocephalosporadesic 14- O-phenylalanyl-7-\(oz-hydroxythien-2-ylacetamido)- cephalosporadesic acid O-phenylalanyl-7-( a-aminophenylacetamido )cephalosporadesic acid O-phenylalanyl-7-( oz-amino-l ,4-cyclo hexadienl ylacetamido )cephalosporadesic acid O-phenylalanyl-7(a-aminothiemZ-ylacetamido)- cephalosporadesic acid.

EXAMPLE 27 cep hali sporadesicg acid I V O methionyl-7( a-a'mimiphenylacetamido )cephalosporadesic acid O-niet hionyl-i('d-amino-'IQ4-cylohexadien 1 ylacctamidoQcephalosporadesiC acid O-methionyl-f/Kd arninothien-ZZ-ylacetamido)cephalosporadesic acid? i EXAMPLE 28 Using N,Ndi-t-buto tycarbonyllysine, N,N'- carbonyldiimidazole and the appropriate sodium 7:acylcephalosporadesate according to the procedure of Example 4, the following products are obtained:

' O lysylr7( 4-pyridylthioacetarnido )cephalosporadesic a'cid O -lysyl 7-cyanoacetamidocephalosporadesic acid O-lysyl7-( l-tetrazolylacetamido)cephalosporadesic acid 7 v O-lysyl -I7-(3-sydnofieacetamido)cephalosporadesic O-lysyl- 7-mandelamidophalosporadesic acid O lysyl-7 ('a-hydroxythien 2-ylacetamido)cephalosporadesic acid O-lysyl-7-( oz-amifiophenylacetamido )cephalosporadesic acid O-lysyl-7-( a-aminol ,4-c'yclohexadienl ylacetamido)cephalosporadesic acid O-lysyl-7-( bz-aminothien-2-yl.acetamido) cephalos- I poradesic acid.

EXAMPLE 29 Using Ntbutoxycarbonylaspartic acid B-t-butyl ester, N,N'-carb'onyldiimidaz0le and the appropriate sodium 7-acylcephalosporadesate according to the procedure of Example 4, t he following products are obtained: I 1 "O-aspartyl- 7-( 4-pyridylthioacetamido )cephalos poradesic acid O-a sp'artyl-7-cyanoacetamidocephalosporadesic acid O-a'spartylJ-i l -tet'razolylacetamido)cephalosporadesic acid O-aspartyl-7-( 3-sydnoneacetamido )cephalos poradesic acid i.

O-aspartyl-7-mandelamidocephalosporadesic acid O-aspartyl-7-( a-hydroxythien-Z-ylacetamido )cephalosporadesic acid O-aspartyl-7-(a-aminophenylacetamido)cephalosporadesic acid O-aspartyl-7-( a-aminol ,4-cyclohexadienl ylacetamido)cephalosporadesic acid O-aspartyI-7-( a-aminothien-Z-ylacetamido )cephalosporadesic acid.

EXAMPLE 30 Using N-t-butoxycarbonyl-B-alanine,

of Example 4, the following products are obtained:

O-(,B-alanyl)-7-(4-pyridylthioacetamido)cephalosporadesic acid O-(B-alanyl)-7-cyanoacetamidocephalosporadesic acid O-(B-alanyl)-7-( l-tetrazolylacetamido )cephalosporadesic acid O-( ,B-alanyl )-7-( 3-sydnoneacetamido )cephalosporadesic acid O-(B-alanyl)-7-mandelamidocephalosporadesic acid O-(B-alanyl )-7-( oz-hydroxythien-2-ylacetamido cephalosporadesic acid O-( ,B-alanyl )-7-( a-aminophenylacetamido )cephalosporadesic acid O(,B-alanyl)-7-( a-aminol ,4-cyclohexadienl ylacetamido)cephalosporadesic acid O-(B-alanyl)-7-( a-aminothien-2 -ylacetamid0 )cephalosporadesic acid.

EXAMPLE 3 1 Using N-t-butoxycarbonyly-aminobutric acid, N,N'- carbonyldiimidazole and the appropriate sodium 7-acylcephalosporadesate according to the procedure of Example 4, the following products are obtained:

O-( 'y-aminobutyryl )-7-( 4-pyridylthioacetamido cephalosporadesic acid O-(y-aminobutyryl )-7- cyanoacetamidocephalosporadesic acid I O-(y-aminobutyryl )-7-( l-tetrazolylacetamido )cephalosporadesic acid O-(y-aminobutyryl )-7-( 3-sydnoneacetamido )cephalosporadesic acid O-( 'y-aminobutyryl )-7-mandelamidocephalosporadesic acid O-( y-aminobutyryl )-7-( a-hydroxythien-Z- ylacetamido)cephalosporadesic acid O-( y-aminobutyryl )-7-( a-aminophenylacetamido cephalosporadesic acid O-(y-aminobutyryl)-7-( oc-amino-l ,4-cyclohexadienl-ylacetamido)cephalosporadesic acid O-(y-aminobutyryl )-7-( a-aminothien-Z- ylacetamido)cephalosporadesic acid.

EXAMPLE 32 Using N-t-butoxycarbonyl-S-aminovaleric O(S-aminovaleryU-7-(4-pyridylthioacetamido cephalosporadesic acid O-(S-aminovaleryl )-7- cyanoacetamidocephalosporadesic acid N,N- carbonyldiimidazole and the appropriate sodium 7-acylcephalosporadesate according to the procedure acid, N,N'-carbonyldiimidazole and the appropriate sodium 7-acylcephalosporadesate according to the procedure of Example 4, the following products are obtained:

and acylaminocephalosporadesate according to the procedure of Example 3, the following products are obtained:

O-( -aminovaleryl 7-( l-tetrazolylacetamido )cephalosporadesic acid O-(8-aminovaleryl)-7-('3-sydnoneacetamido)cephalosporadesic acid O-( S-aminovaleryl )-7-mandelamidocephalosporadesic acid A I O-(6-aminovaleryl)-7-(a-hydroxythien-2- ylacetamido)cephalosporadesic acid O-(o-aminovaleryl)-7-(a-aminophenylacetamido)- cephalosporadesic acid- O-( S-aminovaleryl )-7-( a-amino-l ,4-cyclohexadienl-ylacetamido)cephalosporadesic acid O-(S-aminovaleryl)-7-(a-aminothien-2- ylacetamido)cephalosporadesic acid.

EXAMPLE 33 Using methoxyacetic acid, N,N-carbonyldiimidazole the appropriate sodium 7- O-methoxyacetyl-7-( 4-pyridylthioacetamido )cephalosporadesic acid O-methoxyacetyl-7- cyanoacetamidocephalosporadesic acid O-methoxyacetyl-7 l-tetrazolylacetamido )cephalosporadesic acid O-methoxyacetyl-7-( 3 sydnoneacetamido)cephalosporadesic acid O-methoxyacetyl-7-mandelamidocephalosporadesic I acid O-methoxyacetyl-7-(a hydroxythien-2- ylacetamido)cephalosporadesic acid O-methoxyacetyl-7-(oZ-aminophenylacetamidm-' cephalosporadesic acid O-methoxyacetyl-7-( oz-amino-l ,4-cyclohexadienl ylacetamido)cephalosporadesic acid O-meth0xyacetyl-7-( a-aminothien-2-ylacetamido cephalosporadesic' acid.

EXAMPLE 34 Using B-methoxypropionic acid, N,N'-

carbonyldiimidazole and the appropriate sodium 7- acylaminocephalosporadesate according to the procedure of Example 3, the following products are obtained: 1

EXAMPLE 35 Using y-methoxybutyric acid, N,N'- carbonyldiimidazole and the appropriate sodium 7- acylaminocephalosporadesate according to the procedure of Example 3, the following products are obtained:

O-y-methoxybutyryl-7-(2-thienylacetamido(cephalosporadesic acid O-y-methoxybutyryl-7-(4-pyridylthioacetamido cephalosporadesic acid O-y-methoxybutyryl-7- cyanoacetamidocephalosporadesic acid O-y-methoxybutyryl-7-( 1-tetrazolylacetamido)cephalosporadesic acid O-y-methoxybutyryl-7-( 3-sydnoneacetamido )cephalosporadesic acid O-'y-methoxybutyryl-7mandelamidocephalosporadesic acid O-y-methoxybutyryl-7-(a-hydroxythien-Z- ylacetamido)cephalosporadesic acid O-y-methoxybutyryl-7-(a-aminophenylacetamido)- cephalosporadesic acid O-y-methoxybutyryl-7-(a-amino-1 ,4-cyclohexadienlylacetamido)cephalosporadesic acid O-y-methoxybutyryl-7-(a-aminothiene-2- ylacetamido)cephalosporadesic acid.

EXAMPLE 36 Using S-methoxyvaleric acid, N,N'- carbonyldiimidazole and the appropriate sodium 7-acylcephalosporadesate according to the procedure of Example 3, the following products are obtained:

O-8-methoxyvaleryl-7-( 2-thienylacetamido)cephalosporadesic acid O-6-methoxyvaleryl-7-(4-pyridylthioacetamido)- cephalosporadesic acid O-6-methoxyvaleryl-7- cyanoacetamidocephalosporadesic acid O-8-methoxyvaleryl-7( l-tetrazolylacetamido )cephalosporadesic acid O--methoxyvaleryl-7-( 3-sydnoneacetamido )cephalosporadesic acid O-S-methoxyvaleryl-7-mandelamidocephalosporadesic acid O-8-methoxyvaleryl-7-( oz-hydroxythien-Z- ylacetamido)cephalosporadesic acid O-5-methoxyvaleryl-7-( a-aminophenylacetamido cephalosporadesic acid O-8-methoxyvaleryl-7-(a-amino-1,4-cyclohexadienlylacetamido)cephalosporadesic acid O-8-methoxyvaleryl-7-(a-aminothien-Z- ylacetamido)cephalosporadesic acid.

EXAMPLE 37 When a-ethoxyacetic acid, B-ethoxypropionic acid, 'y-ethoxybutyric acid or S-ethoxyvaleric acid are substituted for the methoxyalkanoic acids in Examples 33-36, respectively, the corresponding 0- ethoxyalkanoyl-7acylaminocephalosporadesic acids are obtained.

What is claimed is:

1. In a method for the preparation of O-acyl-7- acylaminocephalosporadesic acids, the improvement wherein the 3-hydroxymethyl group of a 7- acylaminocephalosporadesic acid is O-acylated by rell R,''C-NH S N 0 CH ,OH

OOM

in which:

R, is benzyl, a-hydroxybenzyl having an O- protecting group, oz-aminobenzyl having an N- protecting group, a-aminocyclohexadienylmethyl having an N-protecting group, thienylmethyl, tetrazolylmethyl, vpyridylthiomethyl, phenoxymethyl, phenylthiomethyl, benzofurylmethyl, isothiazolylmethyl or d-methoxy-3,4-dichlorobenzyl and M is hydrogen, an alkali metal cation or a quaternary ammonium cation. 5. In a method according to claim 4, the improvement wherein the product is an O -acyl-7- acylaminocephalosporadesic :acid of the formula:

C OOM in which:

R is. benzyl, oz-hydroxybenzyl, a-aminobenzyl,

a-aminocyclohexadienylmethyl, thienylmethyl, tetrazolylmethyl, pyridylthiomethyl, phenoxymethyl, phenylthiomethyl, benzofurylmethyl, isothiazolylmethyl or a-methoxy-3,4-dichlorobenzyl;

is an acyl group for antibacterial cephalosporins, except that an easily eliminated B-substituent is not present and M is hydrogen, an alkali metal cation or a quaternary ammonium cation.

6. In a method according to claim 1, the improvement wherein the 7-acylaminocephalosporadesic acid is used in the form of an alkali metal salt.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT NO. 3,905,967 DATED I September 16., 1975 INVENTOR(S) 1 David A. Barges It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Column 1, line l r grup should read group Column 13, line 25, "cyclohexadienb" should read cyclohexadien-l- Column 14, line 46, mandelamidophalosporadesic" should read mandelamidocephalosporadesic Column 16, line 52, "cyanoaceetamidocephalosporadesic" should read cyanoacetamidocephalosporadesic Column 18, line 56, delete [R from the structure.

Signed and Scaled this second D 3) Of March 1976 [SEAL] Arrest:

RUTH C. MASON C. MARSHALL DANN Arresting Officer Commissioner uj'larents and Trademarks 

1. IN A METHOD FOR THE PREPARATION OF O-ACYL-7ACYLAMINOCEPHALOSPORADESIC ACIDS, THE IMPROVEMENT WHEREIN THE 3-HYDROXYMETHYL GROUP OF A 7-ACYLAMINOCEPHALOSPORADESIC ACID IS O-ACYLATED BY REACTING AT ABOUT O* TO 50*C. WITH AN AZOLIDE THE ACYL GROUP OF WHICH AZOLINE MAY NOT CONTAIN AS EASILY ELININATED B-SUBSTITUENT.
 2. In a method according to claim 1, the improvement wherein the azolide is selected from the group consisting of N-acylimidazole, 1-acyl-1,2,4-triazole and 1-acyl-1,2,3-triazole.
 3. In a method according to claim 1, the improvement wherein the azolide is an N-acylimidazole.
 4. In a method according to claim 1, the improvement wherein the 7-acylaminocephalosporadesic acid is of the following formula:
 5. In a method according to claim 4, the improvement wherein the product is an O-acyl-7-acylaminocephalosporadesic acid of the formula:
 6. In a method according to claim 1, the improvement wherein the 7-acylaminocephalosporadesic acid is used in the form of an alkali metal salt. 